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The mitochondrial matrix ATPase associated with diverse
cellular activities (m-AAA) protease spastic paraplegia 7 (SPG7)
has been recently implicated as either a negative or positive reg-
ulatory component of the mitochondrial permeability transi-
tion pore (mPTP) by two research groups. To address this con-
troversy, we investigated possible mechanisms that explain the
discrepancies between these two studies. We found that loss of
the SPG7 gene increased resistance to Ca2-induced mPTP
opening. However, this occurs independently of cyclophilin D
(cyclosporine A insensitive) rather it is through decreased mito-
chondrial Ca2 concentrations and subsequent adaptations
mediated by impaired formation of functional mitochondrial
Ca2 uniporter complexes. We found that SPG7 directs the
m-AAA complex to favor association with the mitochondrial
Ca2 uniporter (MCU) and MCU processing regulates higher
order MCU-complex formation. The results suggest that SPG7
does not constitute a core component of the mPTP but can mod-
ulate mPTP through regulation of the basal mitochondrial Ca2
concentration.
The mitochondrial permeability transition pore (mPTP)2 is a
Ca2- and reactive oxygen species (ROS)-sensitive nonselec-
tive channel of unknown identity that is involved in many
pathologies including ischemia reperfusion injury, Alzheimer’s
disease, amyloid lateral sclerosis, and diabetes (1–5). Over the
past 40 years many models of the mPTP have been hypothe-
sized; often these models rely on the idea that the core pore
forming proteins bind to cyclophilin D (CypD) in a cyclospo-
rine A (CsA)-sensitive manner. This is from the discovery that
the immunosuppressant CsA could dramatically increase the
threshold to mitochondrial Ca2 overload-mediated pore
opening (6, 7). Currently, one of the strongest candidates for the
pore forming unit is the F0F1-ATP synthase, either as dimers or
a dissociation between the F0 and F1 subunits (8, 9). The ATP
synthase binds to CypD through the oligomycin sensitivity con-
ferring protein in a CsA-sensitive manner; displaying conduct-
ance states similar to those observed in the mPTP, has a Mg2
competitive Ca2-binding site, pH sensitivity, and displays sen-
sitivity to other pharmacological regulators of the pore, most
notably benzodiazepines (10 –12).
In contrast to this model there has recently been a report
suggesting that the m-AAA protease spastic paraplegia 7
(SPG7) is an essential part of the mPTP (13). Shanmughapriya
et al. (13) used an unbiased RNAi screen to identify candidates
that when lost increase the calcium retention capacity (CRC) of
human embryonic kidney (HEK) 293T cells independent of
ROS. Additionally, using a yeast two-hybrid and co-immuno-
precipitation technique, Shanmughapriya et al. (13) demon-
strated that the C-terminal portion of SPG7, amino acids 700 –
795, was required for binding to CypD. Concerns have already
been brought forth regarding how loss of the mPTP could lead
to the clinical presentation of spastic paraplegia, as well as some
broader concerns related to interpretation of the data pre-
sented (14). Our main concern was a lack of direct evidence
linking SPG7 as a regulator of the mPTP through CypD. Shan-
mughapriya et al. (13) using human cell lines, created a CypD
mutant that was insensitive to CsA and unable to bind to SPG7.
Expression of this mutant failed to restore the phenotype of the
SPG7 knockdown cells. Unfortunately, one of the sites they
changed, R97G, is the same mutation used to render CypD
isomerase deficient and unable to have any effect on the mPTP
regardless of its binding partner (15). Additionally, in contrast
to the report by Shanmughapriya et al. (13), it was recently
shown that m-AAA– deficient mitochondria exhibited signifi-
cantly reduced CRC and facilitated mPTP opening (16). These
authors also show, using a knockout mouse model, that the loss
of the m-AAA protease AFG3L2, the obligate binding partner
of SPG7, increases mitochondrial Ca2 through regulation of
essential MCU regulator (EMRE) processing and formation of
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ungated mitochondrial Ca2 uniporter (MCU) complexes
(MCUc) (16, 17). In light of these discrepancies, we tested the
ability of SPG7 to regulate the mPTP in a CypD-dependent
manner and found that SPG7 does not constitute a core com-
ponent of the mPTP, but instead regulates mPTP activity by
lowering the basal mitochondrial Ca2 ([Ca2]mt) levels via
regulation of MCU regulator 1 (MCUR1) and MCUc assembly.
Results
Characterization of the SPG7 KO cell line and constructs
In humans SPG7 functions in a hexameric complex in a 1:1
ratio with AFG3L2 but not as a homomeric complex (Fig. 1A).
Therefore m-AAA protease KO HEK cell lines were created
using a CRISPR Cas9 D10A NIckase (18, 19) using paired
sgRNAs described in Table S2. Following 2 weeks of selection
with puromycin, individual colonies were expanded. A geno-
typing protocol to detect the small change in size of an indel by
using primers flanking the targeted cut site was used to verify
knockout (Fig. 1B). The increase in the size of the amplicon
from 327 to 350 bp indicates the presence of an indel in the
SPG7 gene. To rescue the knockout, a CRISPR-resistant full-
length (FL), a C-terminal-truncated (ct, missing amino acids
700 –795 that renders it unable to bind CypD), or a dominant-
negative (DN, mutated Zn2-binding region H574G, E575G,
G577S, rendering it catalytically inactive) SPG7 was used (Fig.
1A) (13). The loss of SPG7 in the knockout and subsequent
rescued cell lines were verified by immunoblotting (Fig. 1C).
These results indicate that we could accurately reproduce
model HEK 293T cell lines with both a loss of and rescue with
SPG7.
SPG7 modulates the mPTP in a manner independent of CypD
To assess the susceptibility of mPTP opening of each cell line,
the CRC of permeabilized WT HEK 293T, the SPG7 KO, as well
Figure 1. CRISPR-mediated deletion and rescue of SPG7. A, top: schematic of the structure of m-AAA proteases. TM, transmembrane spanning amino acids.
Bottom: hexameric assembly of the m-AAA protease complexes in humans. B, representative gel of the PCR product from cDNA isolated from either HEK 293T
control or SPG7 KO cells and schematic of guide RNAs (red) cut site (green arrow) and PAM motif (blue), and PCR strategy to verify the presence of indels by
genotyping. C, representative Western blotting of HEK 293T control, SPG7 KO, FL SPG7 rescue, and ct SPG7 rescue cell lines. The membrane is probed for SPG7
and AFG3L2 with HSP60 as a loading control (n  3).
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as the FL, ct, and DN SPG7 rescue cell lines was determined
(Fig. 2A). In these assays, the addition of CsA was used to
achieve the maximum CRC for each cell population and thus
was served as a reference point (21). The CRC of the WT HEK
293T cells was 34.2  1.3% of the CsA capacity. As shown in
Ref. 13, the loss of SPG7 resulted in a substantial increase in
CRC to 50.6  3.2% of the CsA capacity (Fig. 2). Interestingly,
loss of SPG7 resulted in an 40 nmol increase of both the Ca2
and Ca2  CsA treatment groups versus HEK 293T cells sug-
gesting a greater reservoir for Ca2 uptake (Fig. 2, G and H).
Interestingly, loss of SPG7 did not alter the effects of CsA sug-
gesting that SPG7 and CypD are acting via different mecha-
nisms to open the mPTP. Both the FL and ct SPG7 were able
to reverse the increases in the CRC of the SPG7 KO cell line to
41.8  5.1 and 39.3  8.3% of CsA capacity, respectively, similar
to those of WT HEK 293T cells (Fig. 2). Surprisingly, rescue of
SPG7 KO with the DN SPG7 rescued the cells to mPTP opening
with a CRC of 28.6  1.5% of CsA capacity. This phenocopied
the AFG3L2 KO cells that also had a CRC of 28.6  1.5% of CsA
capacity and reduced both the Ca2 treatment and Ca2  CsA
treatment groups versus HEK 293T cells (Fig. 2, E and F, Fig.
S1A). These results indicate that the resistance to mPTP open-
ing by the loss of SPG7 is acting in a manner independent of
CypD.
Loss of SPG7 reduces mitochondrial matrix Ca2 content and
influx kinetics
The potential mechanisms why SPG7 KO can lead to an
increased CRC were then investigated. We hypothesized that
the [Ca2]mt may be regulated by SPG7 function, which
increases the available reservoir for mitochondria to take up
more Ca2 before mPTP opening occurs. Therefore, the basal
[Ca2]mt was assayed by incubating permeabilized HEK 293T
cells in a solution containing membrane impermanent Fura2-
FF, and thapsigargin to block ER Ca2 uptake, using addition of
3 M FCCP to collapse mitochondrial membrane potential and
release the [Ca2]mt into the incubating solution. Mitochon-
dria in the SPG7 KO cells released 63  24 nM Ca2 versus
284  75 nM Ca2 in HEK 293T cells. Conversely the mito-
chondria from the DN SPG7 cells released 717  197 nM Ca2
(Fig. 3, A and B). To confirm our findings, we measured the
levels of phosphorylated pyruvate dehydrogenase (PDH) at ser-
ine 293 (P-Ser293) as an indirect measurement of [Ca2]mt.
PDH is dephosphorylated by a Ca2-dependent phosphatase,
thus an increase in P-Ser293 PDH is indicative of lower
[Ca2]mt. When assayed via Western blotting, the SPG7 KO
compared with control HEK 293T cells had a P-Ser293 PDH/
total PDH ratio 1.57  0.22 times that of HEK 293T cells,
whereas the DN SPG7 expressing cells had a P-Ser293 PDH/
total PDH ratio of 0.54  0.25 times that of HEK 293T cells (Fig.
3, C and D). Last, to confirm our results the mitochondrial
matrix targeted (Mt) Ca2 probe GCamp6f (22) was trans-
fected into our cell lines. Similar to the two other assays, the
SPG7 KO had less, whereas the DN SPG7 rescue cells had more
[Ca2]mt than HEK 293T cells (Fig. S1, C and D). Because the
[Ca2]mt was affected, alterations in mitochondrial Ca2 influx
was interrogated. Using permeabilized HEK 293T cells in the
Figure 2. Loss of SPG7 increases CRC independent of CypD. A–F, representative traces of [Ca2] clearance (Fura2-FF) of 3.75  106 digitonin-permeabilized
HEK 293T cells pulsed with 10 nmol of Ca2 treated with vehicle (black trace) or 1 M CsA (red trace). B, SPG7 KO. C, FL SPG7 rescue. D, ct SPG7 rescue. E, DN SPG7
rescue. F, AFG3L2 KO. G, chart summarizing the results of A–F. H, quantification of the CRC ratio from A–F (S.D.; n  3– 6). *, p  0.05 versus HEK 293T, individual
values are represented by black dots.
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presence of thapsigargin the SPG7 KO cells took up a bolus of
0.5 M Ca2 at a rate of 41.2  5.47 nM/min versus 58.08  2.02
and 79  0.1.77 nM/min of HEK 293T and DN SPG7 cells,
respectively (Fig. 4, A and B). To ensure that the differences in
influx were not due to alterations of the driving force, mito-
chondrial membrane potential was assessed by the change of
tetramethylrhodamine methyl ester fluorescence after addition
of FCCP; no difference was observed (Fig. S1E). Taken together,
these results indicate that loss of SPG7 is lowering the basal
level of [Ca2]mt content and the rate of Ca2 influx, whereas
loss of both SPG7 and AFG3L2 activity increases basal levels of
[Ca2]mt and the rate of Ca2 influx. From these data we can
infer that alterations in mitochondrial Ca2 handling are likely
a mechanism by which m-AAA proteases regulate tolerance to
Ca2-induced mPTP opening.
Loss of SPG7 alters the MCU complex
To better understand the mechanism behind how Ca2
influx was altered by m-AAA proteases we examined the
expression of components of the MCU complex (Fig. 5, A and
B). The SPG7 KO cells expressed 69.0  7.8% MCUR1 more
than HEK 293T, whereas DN SPG7 expressing cells had
192.5  22.5% MCUR1 more than HEK 293T cells. MCU
expressed 180.5  10.7% that of HEK 293T cells in SPG7 KO
cells, whereas DN SPG7 cells expressed 148.2  11.0% of HEK
293T cells. The 11-kDa unprocessed form of EMRE was
expressed at 46.4  1.2 and 39.4  1.6% in SPG7 KO and DN
SPG7 cells, respectively, when compared with HEK 293T. The
7-kDa processed form of EMRE was expressed at 395.7  31.9%
in SPG7 KO and 175.0  3.5% in DN SPG7 cells when com-
pared with the HEK 293T cells. Last, MICU1 expression was
increased to 184.1  5.0% in SPG7 KO cells relative to HEK
293T cells, whereas DN SPG7 was 102.6  8.4% and not signif-
icantly different from the HEK 293T cells (Fig. 5, A and B).
These data suggested major alterations to MCU stoichiometry
and assembly. Therefore we sought to estimate the changes in
MCU assembly that would lead to alterations in the number of
functional MCUc units; we estimated the SPG7 KO and DN
SPG7 lines have a MCUc functional level of 36  1 and 133 
6% that of HEK 293T cells, respectively (Fig. S2F). To assess if
MCU complex assembly is indeed affected we took advantage
Figure 3. SPG7 regulates basal mitochondrial matrix Ca2 content. A, representative traces of the extramitochondrial [Ca2] (Fura2-FF) of 3.75  106
digitonin-permeabilized HEK 293T (black trace), SPG7 KO (red trace), or DN SPG7 (blue trace) cells in the presence of 2 M thapsigargin. At 2 min, 3 M FCCP is
added. B, quantification of the average change in fluorescence ratio observed between basal state and after addition of 3 M FCCP (S.D.; n  8). C, represen-
tative Western blotting of mitochondria isolated from HEK 293T, SPG7 KO, or DN SPG7 cells. The membrane is probed for SPG7, P-Ser293 PDH, and total PDH. D,
quantification of the average fluorescence intensity of P-Ser293 PDH/total PDH (S.D.; n  4). *, p  0.05 versus HEK 293T, individual values are represented by
black dots.
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of the fact that the MCU complex is partially resistant to dena-
turing SDS-PAGE (23). A C terminally hemagglutinin A (HA)-
tagged MCU was overexpressed and immunoprecipitated to
enrich the MCU complexes resident in each cell line. When
immunoblotted for the HA tag, bands are observed at 34 and 40
kDa, and a faint 45-kDa complex could also be observed in the
SPG7 KO and DN SPG7 input lanes (Fig. 6A). A large increase
in higher order complex formation (40 kDa) in the DN SPG7
sample was present in the immunoprecipitated samples (Fig.
6A). Surprisingly, only when immunoblotted for MCU did we
observe the expected band at 30 kDa. A 60-kDa complex was
also present in the input that could not be immunoprecipitated
by anti-HA as this MCU complex was not recognized by our
HA antibody (Fig. 6A). When the immunoprecipitated com-
plexes were quantified the full-length (FL) 40-kDa MCU was
179.8  21.6 and 627.9  7.8% in the SPG7 KO and DN SPG7
versus HEK 293T cells, respectively (Fig. 6C); the MCU with the
mitochondrial targeting sequence (MTS) removed appearing at
34 kDa was 153.7  12.1 and 235.2  21.3% in SPG7 KO and
DN SPG7 versus HEK 293T cells, respectively (Fig. 6C); last the
3 bands between 34 and 30 kDa we term m-AAA MCU (blue
bracket in Fig. 6A, right) were 283.4  5.9 and 386.8  41.3% in
SPG7 KO and DN SPG7 versus HEK 293T cells, respectively
(Fig. 6C). We expected to observe an accumulation of the
products in each step of MCU processing affected by loss of
SPG7. Therefore, we measured the ratios between the FL and
MTS MCU to observe if the removal of the MTS or the ratio
between the MTS- and 30 –34 kDa m-AAA MCU were
adversely affected.
The MTS/FL MCU ratio remained unchanged at 85.7  6.3%
in the SPG7 KO versus HEK 293T cells and a significant
decrease to 37.4  3.7% in DN SPG7 versus HEK 293T cells (Fig.
6D). We also observed a significant increase to 185.0  12.7% in
the m-AAA/MTS MCU ratio in SPG7 KO versus control that is
similarly present in the DN SPG7 cells, 165.8  28.1%, versus
HEK 293T cells (Fig. 6D). These changes were both likely driven
by increases in the m-AAA levels. To confirm that alterations in
Figure 4. Loss of SPG7 lowers mitochondrial Ca2 influx. A, representative
trace of Calcium Green 5N fluorescence in 3.75  106 digitonin-permeabi-
lized HEK 293T (black trace), SPG7 KO (red trace), and DN SPG7 (blue trace) cells
challenged with 0.5 M Ca2 in the presence of 2 M thapsigargin. B, quanti-
fication of the average slope for the time to reach 50% Ca2 uptake (S.D.; n 
4 –5). *, p  0.05 versus HEK 293T, individual values are represented by black
dots. Figure 5. SPG7 modulates MCU and MCUR1. A, representative Western
blotting of HEK 293T, SPG7 KO, and DN SPG7 cells. The membrane is probed
for SPG7, AFG3L2, YME1L, NCLX, MCUR1, MCU, EMRE, MICU1, MICU2, VDAC,
and HSP60 as a loading control. B, quantification of the average fluorescence
intensity of the indicated bands normalized to HSP60 as a percentage of HEK
293T (S.D.; n  3). *, p  0.05 versus HEK 293T; #, p  0.05 between groups,
individual values are represented by black dots.
SPG7 regulation of the mPTP
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m-AAA activity could drive changes in MCUc formation we
performed a native PAGE of HEK293T, SPG7 KO, DN SPG7,
and MCU KO cells. We observe increased levels of complex
formation at 160.4  10.3 and 227.1  2.0% in SPG7 KO and
DN SPG7 versus HEK 293T cells, respectively (Fig. S1). We
suspect the major functional difference lies in the proportion of
gated versus MCUc. To assess changes in the complex assembly
we estimated the propensity for cells to form the basic func-
tional MCUc unit of MCU  EMRE, factored in the available
subunits for gating via MICU1, and lastly factored in the capac-
ity for MCUc assembly via MCUR1 levels (Fig. S2).
Last, to see if there was a direct interaction between MCU
and SPG7; MCU-HA– and FL SPG7-cMyc–tagged proteins
were overexpressed in SPG7 KO cells and immunoprecipitated
with either anti-HA or anti-cMyc antibody-conjugated beads.
We observed that FL SPG7 was able to co-immunoprecipitate
with MCU when precipitating with either antigen suggesting
strongly that these proteins interact (Fig. 7, A and B). Moreover,
we found no difference in binding affinity between FL SPG7 and
DN SPG7; to our surprise ct SPG7 had an increased affinity for
MCU (Fig. S2, B and C). These results indicate that the MCU
protein is directly modified by the m-AAA protease complex at
the C terminus with increased efficiency when functional
SPG7:AFG3L2 hetero-oligomers are present.
Discussion
The current discrepancy between reports of SPG7 acting as
either a positive or negative regulator of the mPTP led us to
investigate the mechanism of mPTP regulation by SPG7 in
HEK 293T cell lines with a loss of and subsequent rescue of
Figure 6. SPG7 modulates MCU complex assembly. A, Western blotting of immunoprecipitation of HEK 293T, SPG7 KO, or DN SPG7 cells transfected with
MCU-HA probed with either anti-HA (left) or anti-MCU (right) antibodies. Bands representative of higher order MCU complexes (red), MTS processing (green),
and m-AAA protease processing (blue) are highlighted between colored brackets. Dashed red lines indicate splice sites between the merged 700 and 800 nm
channels. B, schematic of the MCU protein. TM: transmembrane. C, quantification of the 40-kDa FL, 34-kDa MTS, and 34 –30 – kDa m-AAA–processed MCU from
the membrane probed with MCU antibody in A normalized to the 50-kDa IgG band (S.D.; n  3). D, quantification of the ratio between MTS/FL MCU and
m-AAA/MTS MCU from C (S.D.; n  3). *, p  0.05 versus HEK 293T, ns  not significant, individual values are represented by black dots.
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SPG7. Using this experimental model we found that the CRC in
SPG7 KO cells was still significantly increased by CsA, which
suggests that CypD is binding to another complex and not
mediating its effects through SPG7. Moreover, rescue of the
SPG7 KO with a mutant of SPG7 that is unable to bind to CypD,
could reverse the increases of CRC by SPG7 KO as well as main-
tain the sensitivity to CsA, which further confirmed CypD is
binding to a protein other than SPG7 to regulate the mPTP.
Strikingly, rather than failing to rescue the KO, rescue with a
DN SPG7 restored the cells mPTP sensitivity, and reduced the
maximum capacity when treated with CsA; phenotypically
identical to loss of AFG3L2. We then investigated the potential
mechanisms of how physical loss of SPG7 (KO) can lead to an
increase in CRC, whereas functional loss (DN) can restore CRC.
Using both a direct [Ca2]mt release assay and the P-Ser293
PDH/total PDH ratio as a “bio-sensor,” we found that the loss of
SPG7 led to lower basal levels of [Ca2]mt, whereas expression
of DN SPG7 increased the levels, which closely mirrors the
trend of the CRC data. It is important to note there is a large
discrepancy between the values in Ca2 taken up by the CRC
assay and those determined by the Ca2 release assay. Although
the SPG7 KO could take up 40 nmol of additional Ca2/3.75 
106 cells versus HEK 293T cells before mPTP opening, yet there
was only a difference of 0.4412 nmol of Ca2 released between
SPG7 KO and HEK 293T cells in the Ca2-release assay. One
possible mechanism could be how the cells adapt to loss of
SPG7 and the resulting sustained lower [Ca2]mt. It was
recently shown that mice lacking MCU from birth compen-
sated to the lower basal [Ca2]mt by sensitizing the mPTP
threshold via phosphorylation on CypD (24). The authors
hypothesize that the reduced [Ca2]mt lowers the activity of the
Ca2-dependent phosphatases present, thus raising the basal
level of phospho-CypD/total CypD, and thus its affinity to reg-
ulate the mPTP. It is possible a similar mechanism may be at
play in the SPG7 KO cells; after 20 passages in culture the cells
CRC began to normalize toward a similar capacity as WT cells.
However, there was also a corresponding increase in AFG3L2
expression (data not shown).
Two recent reports suggested that the m-AAA proteases,
of which SPG7 and AFG3L2 are members, can regulate
[Ca2]mt through the processing of EMRE (16, 17). However,
both of these studies focused on the protein AFG3L2, which
can form a homo-oligomer or hetero-oligomer with SPG7.
Because SPG7 does not form functional homo-oligomers, we
reasoned it may be responsible for targeting the m-AAA pro-
tease to a different substrate of the mitochondrial Ca2
import machinery than the AFG3L2 homo-oligomers. This
role was previously reported for SPG7’s ability to target the
m-AAA complex to process complex 1 of the electron trans-
port chain independent of SPG7 proteolytic activity (26).
Therefore, we measured the relative protein expression for
the MCU complex components for [Ca2]mt influx and
NCLX to see if [Ca2]mt efflux was altered. The loss of SPG7
significantly affected MCU, EMRE, MICU1, and MCUR1
levels, suggesting there may be alterations in functional
MCU complex assembly.
To explore this, we immunoprecipitated HA-tagged MCU
and looked at higher order complex assembly. To our surprise,
we saw a difference in the bands identified by the anti-HA and
anti-MCU antibodies. The HA antibody does not recognize
proteins lower than 34 kDa. 34 kDa is the predicted molecular
mass for MCU after processing by the mitochondrial pro-
cessing peptidase, which is largely responsible for removing
positively charged N-terminal mitochondrial targeting pre-se-
quences (27). MCU is predicted to lose the first 50 –55 amino
acids reducing the total molecular mass from 40 to 34 kDa (28,
29). Furthermore, the appearance of multiple bands between 34
and 30 kDa only recognized by the MCU antibody suggests
MCU is being cleaved C terminally in a processive fashion, one
of the key hallmarks of AAA-proteases, rather than a site-spe-
cific peptidase (30). Another striking difference between the
DN and SPG7 KO was the presence of a 45-kDa band greatly
increased in the DN SPG7 KO. We hypothesize that this is the
ungated MCU:EMRE complex described in previous studies on
AFG3L2-mediated regulation of MCU (16, 17). 45-kDa is the
size one would expect of unprocessed EMRE (11 kDa) bound to
the 34-kDa MTS-processed MCU. We believe the change in
this complex is largely responsible for the disparity between the
SPG7 KO, which preferentially targets the m-AAA hexamer to
process MCU, and DN SPG7, which affects MCU processing
and EMRE processing through its inhibition of AFG3L2. We
observed that SPG7 KO has a minimal effect on the processing
Figure 7. SPG7 interacts directly with MCU. Western blotting of SPG7 KO
cells transfected with FL-SPG7 cMyc, MCU-HA, or both plasmids were
immunoprecipitated (IP) with beads conjugated with anti-cMyc tag (A) or
anti-HA (B) antibodies. Membranes were probed with anti-HA tag and
cMyc antibodies.
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from FL MCU to MTS MCU yet the DN SPG7 has a profound
effect on this process. It is likely that the available pool of
functional AFG3L2 homo-oligomers is reduced through
overexpression of DN-SPG7, which integrates into the
AFG3L2 complex. The remaining pool of functional
AFG3L2 homohexamers is likely overwhelmed with sub-
strate and the resulting backup of mitochondrial protein
turnover leads to loss of protein homeostasis and degrada-
tion. This ultimately results in an accumulation of interme-
diate forms of all m-AAA protease substrates; whereas loss
of SPG7 affects a select subset of substrates leaving the
majority of mitochondrial proteins available to turnover at a
level the cell can compensate.
One open question we did not extensively explore is if SPG7
is directly regulating MCUR1 or if the change in expression we
observed was due to lack of fully processed MCU to aid with
stabilizing the MCUR1 protein scaffold. Overexpression of
MCUR1 in SPG7 KO and HEK 293T cells displayed reduced
25-kDa processed MCUR1 in the KO, but unlike with MCU
overexpression, no increased appearance of the 37-kDa form.
However, in DN SPG7 cells, overexpression of MCUR1 resulted
in an increase in the full-length MCUR1 at 37 kDa as well as
more 25-kDa MCUR1, suggesting that AFG3L2 may be respon-
sible for clearance and turnover of MCUR1 (data not shown).
The MCU residues identified as essential to binding to MCUR1
were amino acids 150 –220 in the N-terminal domain region
and to a lesser extent amino acids 291–320 (31). Based on the
observed 30-kDa size of MCU we would expect the m-AAA
protease to remove the C-terminal amino acids up to
approximately amino 314 –320 leaving the MCUR1-binding
regions largely intact. The loss of MCUR1 itself has a signif-
icant impact on Ca2 sensitivity and threshold for opening
of the mPTP (32). MCUR1 may act as a link between the
MCU complex and the mPTP, thus less MCUR1 would keep
Ca2 influx, and the high Ca2 nanodomains present at the
MCU complex, separate from the mPTP; an idea affirmed by
the observation that mitochondria can handle more Ca2
with a steady slow infusion of Ca2 versus a large bolus
where rapid influx results in temporary nanodomains of high
Ca2 due to the slower kinetics of the phosphate buffering
(17). Indeed, loss of the C-terminal amino acids on MCU
may be essential to exposing the MCUR1-binding site for
efficient complex assembly.
When König et al. (16) knocked out SPG7 in their model they
observed no change in CRC capacity, in contrast to both Shan-
mughapriya et al. (13) and our data. We believe the key differ-
ence is that they used a murine model, which also expresses the
m-AAA protease AFG3L1 and was lost as a pseudogene in
humans (20). Because AFG3L1 can form functional homohex-
amers as well as heterohexamers with AFG3L2 and SPG7 it is
likely the loss of SPG7 alone can be compensated for as one of
these murine-specific complexes may be able to efficiently tar-
get MCU. Indeed, the major differences between AFG3L1 and
AFG3L2 reside in the N-terminal region, which is suggested as
a domain that contributes to substrate recognition (30). Even
though SPG7 is different from both AFG3L1 and AFG3L2 at
the N terminus, rescuing the SPG7 KO cells with AFG3L1
restored the CRC phenotype back to WT as well as the basal
Ca2 as assessed by Mt GCamp6f fluorescence. It is possible
that rather than revealing a novel targeting motif the AFG3L1
and SPG7 subunits mask the AFG3L2-targeting site, which
excludes substrates; a hypothesis we cannot rule out especially
because SPG7 and AFG3L1 are quite different in the N-termi-
nal motifs.
Whether SPG7 is acting solely through substrates of the
MCU complex and we are observing an epistatic effect on
mPTP regulation cannot be ruled out; the evidence there were
no changes in ROS sensitivity of the mPTP in SPG7 KO, no
changes in mitochondrial membrane potential, and that DN
SPG7 expression did not alter the Ca2 levels in MCU KO cells
leads us to conclude that changes in MCUc formation are likely
the primary mechanism of action (Fig. 8, Fig. S1).
Our study investigated possible mechanisms for how
m-AAA proteases could be both a positive and negative regu-
lator of the mPTP. We conclude that SPG7 is not an essential
component of the mPTP through its interaction with CypD, but
rather a key regulator of the assembly of the mitochondrial
Ca2 influx mechanism. Loss of SPG7 reduces MCU pro-
cessing as well as MCUR1 levels, whereas inhibition of all
m-AAA protease activity has the opposite effect. Loss of SPG7
reduces the capacity for mitochondria to uptake Ca2 at lower
concentrations of Ca2 as well as decreasing the basal resting
state of [Ca2]mt by reducing the number of fully functional
MCU complexes. A chronic decrease in basal [Ca2]mt ulti-
mately leads to compensatory effects in the mitochondria that
alter the mPTP threshold and Ca2 sensitivity. Expression of
DN-SPG7/loss of AFG3L2 further reduces the total pool of
functional m-AAA proteases resulting in loss of mitochondrial
protein homeostasis, formation of ungated MCU:EMRE chan-
nels, and increased levels of MCUR1. This ultimately leads to an
increased basal [Ca2]mt and mPTP sensitivity.
Experimental procedures
Materials
All materials and reagents used in this study are described in
Tables S1–S3.
Cell culture
HEK 293T cells (ATCC, CRL-3216) were grown in high-glucose
Dulbecco’s modified Eagle’s minimum essential medium (Fisher
Scientific) supplemented with 10% heat-inactivated fetal bovine
serum (Gibco) and 1% penicillin/streptomycin (Corning). Cells
were kept in an incubator at 37 °C with 5% CO2.
Development of CRISPR knockout cell lines
The Cas9 D10A NIckase-2A Puro enzyme and U6 promoter
and empty sgRNA site (Addgene) were each subcloned into
modified pRSET vector with either a cytomegalovirus pro-
moter system or with no promoter and terminator sequence.
The sgRNAs were inserted into the empty sgRNA guide vector
via Q5 site-directed mutagenesis and verified by DNA sequenc-
ing (Genscript) using the U6 Fwd Seq primer. Each sgRNA with
promoter was PCR amplified and purified for Golden Gate
Assembly to form a functional pair of guide RNAs using the
primers indicated in Table S3. Final sgRNA vector was verified
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by DNA sequencing (Genscript) using the sgRNA seq Fwd and
sgRNA seq Rev primers (Table S3). HEK 293T cells were trans-
fected with 1 g of Cas9 D10A NIckase plasmid and 2 g of the
sgRNA pair plasmid. Cells were selected with 1 g/ml of puro-
mycin for 2 weeks. Single cells were then clonally isolated and
verified by PCR-genotyping of flanking regions of the targeted
cut site and/or Western blotting.
Transfection
Cells plated in a 35-mm dish at 80% confluence were trans-
fected by adding 3 g of plasmid to 100 l of Xfect Buffer,
mixed, and 0.9 l of nanoparticles (Clontech) were added to the
tube and vortexed. The DNA:nanoparticle complex was added
dropwise to the cells and incubated for 2 h at 37 °C before
replacing the media with 2 ml of standard culture media. Cells
are assayed or begin selection for stable cell lines at 48 h post
transfection.
Western blotting
Protein content was quantified using a BCA protein assay
(Thermo Fisher Scientific). Equal quantities of protein for each
sample was diluted in Laemmli buffer (60 mM Tris, 5% -mer-
captoethanol, 2% sodium dodecyl sulfate, 10% glycerol, 0.01%
bromphenol blue, pH 6.8). Primary antibodies (see Table S2)
were diluted in PBS-T (0.05% Tween) as follows: 1:200:
AFG3L2, MICU1, PDH E1-A, and NCLX; 1:500: EMRE; 1:1000:
Figure 8. Central hypothesis. Schematic of m-AAA protease processing and regulation of MCU in the mitochondria. Loss of SPG7 KO reduces targeting of the
hexameric m-AAA protease to MCU, whereas expression of DN SPG7 reduces total m-AAA capacity resulting in overwhelmed processing. These alterations
change the stoichiometry and balanced assembly of the MCUc components, leading to reduced or disrupted basal [Ca2]mt that can desensitize (SPG7 KO) or
sensitize (DN SPG7) mPTP opening.
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SPG7, MCU, and MICU2; 1:2000: cMyc and HA; 1:5000:
VDAC; 1:10,000: P-Ser293 PDHE1-A. Secondary antibodies
were diluted 1:20,000 in PBS-T (0.05% Tween). Membrane was
read by an Odyssey Classic machine (LI-COR). Image was ana-
lyzed using Image Studio Lite Software (LI-COR).
Native gel electrophoresis
Equal quantities of protein for each sample samples were
diluted in Native Buffer (60 mM Tris, 10% glycerol, 0.01% bro-
mphenol blue, pH 6.8) and run on a 4 –20% PAGE gel (Bio-Rad).
Membranes are probed with Ponceau stain (0.1% Ponceau S, 1%
acetic acid, v/v) and subsequently immunoprobed using anti-
MCU 1:1000 as described under “Western blotting.”
Estimation of MCUc assembly
As the exact stoichiometry between MCUc remains unknown,
using the protein expression determined by Western blotting we
determined the capacity to form the minimal functional MCUc
unit comprised of EMRE and MCU. To determine whether the
complex was gated we divided the minimal MCUc unit capacity by
MICU1 expression. Last, to estimate the capacity to assemble the
complex we multiplied the gated MCUc by the availability of the
assembly factor, MCUR1.
MCUc assembly
 ((MCU  EMRE(11 kDa 7 kDa))/MICU1)  MCUR1 (Eq. 1)
Immunoprecipitation
Cell lysate was prepared from transiently transfected cells
using 1 lysis buffer (Cell Signaling Technologies) with prote-
ase and phosphatase inhibitor cocktails (Biotool). Cells are
cleared by centrifugation at 2000  g for 5 min at 4 °C. 10%
Lysate was reserved as input. Anti-HA– or myc tag– conjugated
magnetic beads were added to the remaining lysate as per the
manufacturer’s instructions and incubated 2 h at room temper-
ature while shaking. Beads are washed 3 times with PBS and
eluted in Laemmli buffer (60 mM Tris, 5% -mercaptoethanol,
2% sodium dodecyl sulfate, 10% glycerol, 0.01% bromphenol
blue, pH 6.8) incubated at 95 °C for 5 min. Input and immuno-
precipitation elute were subsequently analyzed by Western
blotting.
Calcium retention capacity
HEK 293T cells were counted and resuspended to a con-
centration of 12.5  106 cells/ml in mitochondrial assay
buffer (20 mM Tris, 150 mM sucrose, 50 mM KCl, 2 mM
KH2PO4, and 5 mM succinate, 20 M EGTA). 300 l of cell
suspension (3.75  106 cells) was transferred to each of 4
cuvettes containing 1.7 ml of mitochondrial assay buffer
supplemented with 2 M thapsigargin, 0.6 M JC1, and 0.5
M Fura2-FF. 1 M CsA was added to 2 of the 4 cuvettes.
Cuvettes were placed into a Cary Eclipse fluorescent spec-
trophotometer. Digitonin (20 M) was added at 1 min and,
starting at 5 min, 40 nmol of CaCl2 was added and 10 nmol of
CaCl2 every 2 min after until mPTP was opened.
Assessment of mitochondrial Ca2 content and membrane
potential
HEK 293T cells were counted and resuspended to a concen-
tration of 12.5  106 cells/ml in mitochondrial assay buffer. 300
l of the cell suspension (3.75  106 cells) was transferred to
each of 4 cuvettes containing 1.7 ml of mitochondrial assay
buffer supplemented with 2 M thapsigargin, and 0.5 M
Fura2-FF (Ca2) or 1 M tetramethylrhodamine methyl ester
(membrane potential), and 20 M digitonin. Cuvettes were
placed into a Cary Eclipse fluorescent spectrophotometer. At 2
min of basal recording 3 M FCCP was added to release
[Ca2]mt.
Alternatively, HEK 293T cells were transfected with Mt
GCamp6f. After 48 h images were collected using GFP filters
(excitation 488 nm, emission 510 nm) and 20 –50 cells were
acquired at 40 using an Olympus FV1000 confocal micro-
scope per experiment. Background corrected cell fluorescence
was obtained and normalized to the average fluorescence/cell
in each experiment.
Assessment of mitochondrial Ca2 kinetics
HEK 293T cells were counted and resuspended to a con-
centration of 12.5  106 cells/ml in mitochondrial assay
buffer. 300 l of the cell suspension (3.75  106 cells) was
transferred to 1 of 2 cuvettes, each containing 1.7 ml of mito-
chondrial assay buffer supplemented with 2 M thapsigargin,
and 0.5 M calcium green, 5 N hexapotassium salt, and 20 M
digitonin. Cuvettes were placed into a Cary Eclipse fluores-
cent spectrophotometer.
10 nmol of CaCl2 was added (0.5 M final to each cuvette) and
read for 5 min. The rate of Ca2 clearance was calculated as the
average slope from addition to reach 50% Ca2 clearance.
Ligation independent cloning
pcDNA3.1 Hygro vectors with the Multiple Cloning Site
were replaced with a ligation independent cloning site (TTCG-
CAGGAGCGGCCGCTCCGCTGAA) and in-frame tag or tar-
geting signal insertion sites via a Q5 site-directed mutagenesis
kit (New England Biolabs) and the primers indicated in Table
S3. Vectors were linearized with NotI and treated with T4 DNA
polymerase in the presence of only dTTP. Target Genes were
PCR amplified from cDNA from human or mouse heart tissue
with the primers indicated in Table S3. Agarose gel was purified
and treated with T4 DNA polymerase in the presence of only
dATP. Insert and vector are mixed at a ratio of 3/1 and trans-
formed into New England Biolabs 10- bacteria. Plasmids are
verified by DNA sequencing (Genscript). DN SPG7 vectors
were generated using Q5 site-directed mutagenesis and the
primers indicated in Table S2.
Statistical analysis
Data for multiple experiments were quantified and
expressed as mean  S.E. where indicated. Differences
between groups were determined using independent
Student’s t test. Differences in means among multiple groups
were analyzed using one-way analysis of variance with a Bon-
ferroni’s and Tukey’s post hoc test to determine significance
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between groups. Statistical significance was set at a thresh-
old of p  0.05. The data were computed using SPSS version
23.0.0 software.
Author contributions—S. H. and S.-S. S. conceptualization; S. H. and
A. B. investigation; S. H. and S.-S. S. methodology; S. H. writing-
original draft; S. H., G. C., and S.-S. S. writing-review and editing;
S.-S. S. supervision; S.-S. S. funding acquisition.
Acknowledgments—We acknowledge Sergio DeLaFuente-Perez, Celia
Fernandez-Sanz, Yuexing Yuan, Sebastian Lanvermann, Stephan
Attilus, and Jennifer Wilson for their valuable comments and sugges-
tions in preparation of this manuscript.
References
1. Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A. A., McKhann, G. M., Yan,
Y., Wang, C., Zhang, H., Molkentin, J. D., Gunn-Moore, F. J., Vonsattel,
J. P., Arancio, O., Chen, J. X., and Yan, S. D. (2008) Cyclophilin D defi-
ciency attenuates mitochondrial and neuronal perturbation and amelio-
rates learning and memory in Alzheimer’s disease. Nat. Med. 14,
1097–1105 CrossRef Medline
2. Martin, L. J., Fancelli, D., Wong, M., Niedzwiecki, M., Ballarini, M.,
Plyte, S., and Chang, Q. (2014) GNX-4728, a novel small molecule drug
inhibitor of mitochondrial permeability transition, is therapeutic in a
mouse model of amyotrophic lateral sclerosis. Front. Cell Neurosci. 8,
433 Medline
3. Shiga, Y., Onodera, H., Matsuo, Y., and Kogure, K. (1992) Cyclosporin A
protects against ischemia-reperfusion injury in the brain. Brain Res. 595,
145–148 CrossRef Medline
4. Gomez, L., Paillard, M., Thibault, H., Derumeaux, G., and Ovize, M.
(2008) Inhibition of GSK3 by postconditioning is required to prevent
opening of the mitochondrial permeability transition pore during reper-
fusion. Circulation 117, 2761–2768 CrossRef Medline
5. Ding, Y., Fang, H., Shang, W., Xiao, Y., Sun, T., Hou, N., Pan, L., Sun, X.,
Ma, Q., Zhou, J., Wang, X., Zhang, X., and Cheng, H. (2015) Mitoflash
altered by metabolic stress in insulin-resistant skeletal muscle. J. Mol.
Med. 93, 1119 –1130 CrossRef Medline
6. Fournier, N., Ducet, G., and Crevat, A. (1987) Action of cyclosporine on
mitochondrial calcium fluxes. J. Bioenerg. Biomembr. 19, 297–303
CrossRef Medline
7. Crompton, M., Ellinger, H., and Costi, A. (1988) Inhibition by cyclosporin
A of a Ca2-dependent pore in heart mitochondria activated by inorganic
phosphate and oxidative stress. Biochem. J. 255, 357–360 Medline
8. Alavian, K. N., Beutner, G., Lazrove, E., Sacchetti, S., Park, H.-A., Liczner-
ski, P., Li, H., Nabili, P., Hockensmith, K., Graham, M., Porter, G. A., and
Jonas, E. A. (2014) An uncoupling channel within the c-subunit ring of the
F1FO-ATP synthase is the mitochondrial permeability transition pore.
Proc. Natl. Acad. Sci. U.S.A. 111, 10580 –10585 CrossRef
9. Giorgio, V., Stockum, von, S., Antoniel, M., Fabbro, A., Fogolari, F., Forte,
M., Glick, G. D., Petronilli, V., Zoratti, M., Szabó, I., Lippe, G., and Ber-
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